FG-24-099: Congressionally Directed Spending Projects
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Substance Abuse and Mental Health Services Adminis notices from 2024.
Substance Abuse and Mental Health Services Adminis offered grants of up to $4.5 million to the applicants described in the notice. It expected to make about 92 awards. Applications closed on June 21, 2024.
From the official notice on Grants.gov, last changed April 25, 2024. Checked November 7, 2026.
- Award ceiling$4.5 million
- Expected awards92
- Cost sharingNot required
- Funding typeGrant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| FG-26-099 | June 12, 2026 | Closed July 13, 2026 | Closed |
Key dates
| Posted | April 22, 2024 |
|---|---|
| Deadline | June 21, 2024 |
| Archived by Grants.gov | July 21, 2024 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligibility is limited to CDS Projects authorized under the Further Consolidated Appropriation Act, 2024 [P.L. 118-47].
Is this a realistic fit?
- Past Congressional Directives awards averaged $1.5 million; this notice allows up to $4.5 million per award.
- No cost sharing or match is required.
What the grant funds
CDS projects align with SAMHSA's mission to lead public health and service delivery efforts that promote mental health, prevent substance misuse, and provide treatments and supports to foster recovery while ensuring equitable access and better outcomes. Recipients are expected to fully implement the projects that were approved by Congress. With this program, SAMHSA aims to award resources enacted in the FY 2024 Further Consolidated Appropriation Act.
Who has won Congressional Directives grants before
From fiscal 2021 to 2025, Congressional Directives (93.493) awarded $4.0 billion across 2,688 grant awards, an average of $1.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Alabama at Birmingham | Alabama | 2 | $152 million |
| University of Missouri System | Missouri | 2 | $122 million |
| Missouri State University | Missouri | 3 | $62.5 million |
| University of Kansas Medical Center Research Institute, Inc. | Kansas | 6 | $41.6 million |
| Spring Hill College | Alabama | 1 | $35.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is FG-24-099 still open?
No. It closed on June 21, 2024.
Who can apply for Congressionally Directed Spending Projects?
Substance Abuse and Mental Health Services Adminis accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Congressionally Directed Spending Projects?
Closed June 21, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $4.5 million each.
Who has won Congressional Directives grants before?
The largest recipients over five fiscal years were University of Alabama at Birmingham, University of Missouri System, Missouri State University. The program made 2,688 awards worth $4.0 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)